Literature DB >> 7968028

Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam.

E S Go1, C Urban, J Burns, B Kreiswirth, W Eisner, N Mariano, K Mosinka-Snipas, J J Rahal.   

Abstract

A nosocomial outbreak of infections due to imipenem-resistant Acinetobacter baumannii occurred in a New York hospital after increased use of imipenem for cephalosporin-resistant klebsiella infections. We identified all A baumannii isolates over 12 months, reviewed corresponding patient records, and compared strains with different antibiotic susceptibility patterns by restriction endonuclease analysis. Environmental surveillance cultures were done before and after institution of control measures. 59 patients harboured imipenem-resistant A baumannii, and 18 were infected. Isolates from patients were resistant to all routinely tested antibiotics, including imipenem. Further studies showed susceptibility to polymyxin B and sulbactam. These isolates were identical by restriction endonuclease analysis to A baumannii isolates susceptible to imipenem alone, or to imipenem and amikacin, but differed from broadly susceptible isolates. Surveillance cultures showed hand and environmental colonisation by imipenem-resistant strains. Infection and colonisation were eliminated by intensive infection control measures, and irrigation of wounds with polymyxin B. Increased use of imipenem against cephalosporin-resistant klebsiella may lead to imipenem resistance among other species, particularly acinetobacter. Such resistance appears to derive from a prior multi-resistant clone, in contrast to one which retains susceptibility to several antibiotics.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7968028     DOI: 10.1016/s0140-6736(94)90694-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  76 in total

1.  Skin carriage of acinetobacters in Hong Kong.

Authors:  Y W Chu; C M Leung; E T Houang; K C Ng; C B Leung; H Y Leung; A F Cheng
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

Review 2.  How do you choose antibiotic treatment?

Authors:  L Leibovici; I Shraga; S Andreassen
Journal:  BMJ       Date:  1999-06-12

Review 3.  All great truths are iconoclastic: selective decontamination of the digestive tract moves from heresy to level 1 truth.

Authors:  Hendrick K F van Saene; Andy J Petros; Graham Ramsay; Derrick Baxby
Journal:  Intensive Care Med       Date:  2003-04-10       Impact factor: 17.440

4.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

5.  Longitudinal epidemiology of multidrug-resistant (MDR) Acinetobacter species in a tertiary care hospital.

Authors:  Ji Hoon Baang; Peter Axelrod; Brooke K Decker; Andrea M Hujer; Georgia Dash; Allan R Truant; Robert A Bonomo; Thomas Fekete
Journal:  Am J Infect Control       Date:  2011-08-11       Impact factor: 2.918

6.  Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii.

Authors:  L A Arroyo; A García-Curiel; M E Pachón-Ibañez; A C Llanos; M Ruiz; J Pachón; J Aznar
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

7.  Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.

Authors:  Patrick J Gavin; Mira T Suseno; Richard B Thomson; J Michael Gaydos; Carl L Pierson; Diane C Halstead; Jaber Aslanzadeh; Stephen Brecher; Coleman Rotstein; Stephen E Brossette; Lance R Peterson
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

8.  Vaccination with outer membrane complexes elicits rapid protective immunity to multidrug-resistant Acinetobacter baumannii.

Authors:  Michael J McConnell; Juan Domínguez-Herrera; Younes Smani; Rafael López-Rojas; Fernando Docobo-Pérez; Jerónimo Pachón
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

9.  Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1.

Authors:  C Urban; N Mariano; J J Rahal; E Tay; C Ponio; T Koprivnjak; J Weiss
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

10.  Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan.

Authors:  Lu-Cheng Kuo; Lee-Jene Teng; Chong-Jen Yu; Shen-Wu Ho; Po-Ren Hsueh
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.